Promising long and short-term clinical data show potential of first ASD occluder with a bioresorbable, metal-free frame

atHeart Medical announced promising long and short-term clinical outcomes of its reSept ASD occluder, to be presented at the medical conference CSI Frankfurt.

atHeart Medical Receives FDA Approval for the Second Phase of the ASCENT ASD U.S. IDE Trial

atHeart Medical today announced it has received approval for the start of the second phase of its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial.

First Five Patients Successfully Treated with reSeptTM ASD Occluder in U.S. IDE Pivotal Trial

atHeart Medical announced today the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder.

atHeart Medical has commenced operations and is initiating its U.S. IDE trial.

atHeart Medical announced today that it has commenced operations and is initiating its U.S. Investigational Device Exemption (IDE) trial.

Sigler M, Söderberg B, Schmitt B, Mellmann A, Bernhard J.

Carag bioresorbable septal occluder (CBSO): histopathology of experimental implants.

EuroIntervention. 2018 Feb 20;13(14):1655-1661

Callegari A, Quandt D, Nordmeyer J, Schubert S, Kramer P, Knirsch W, Kretschmar O.

Transcatheter Closure of Atrial Septal Defect with Carag Bioresorbable Septal Occluder: First-in-Child Experience with 12-MonthFollow-Up.

Journal of Interventional Cardiology. Volume 2022, Article ID 3476398, 4 pages

Sievert K, Bertog S, Söderberg B, Gafoor S, Hofmann I, Grunwald I, Schnelle N, Sievert H.

Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable septal occluder: first-in-man experience with 24-month follow-up.

EuroIntervention. 2022 Apr 22;17(18):1536-1537